Trial Profile
A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Prednisone (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 21 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2013 Planned end date changed from 1 Jan 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 12 Apr 2012 Planned end date changed from 1 Dec 2010 to 1 Jan 2013 as reported by ClinicalTrials.gov.